echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hengrui Class 1 antifungal drug Phase III clinical success plans to be listed in the near future

    Hengrui Class 1 antifungal drug Phase III clinical success plans to be listed in the near future

    • Last Update: 2021-12-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On November 4, Hengrui Medicine announced the effectiveness and safety of its new class 1 drug SHR8008 capsule in the treatment of acute vulvovaginal candida disease.


    Hengrui will submit an application for communication and exchange of new drugs to the Drug Evaluation Center of the State Drug Administration in the near future


    SHR8008 is a new type of oral azole antifungal drug, which can highly specifically inhibit the fungal CYP51 enzyme.


    The SHR8008-302 study that reached the endpoint is a randomized, double-blind, double-simulated, fluconazole parallel-controlled, multi-center phase III clinical study evaluating the effectiveness and safety of SHR8008 capsules in the treatment of acute vulvovaginal candidiasis


    Up to now, the accumulated research and development expenses of SHR8008 related projects are about 89.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.